Cargando…
Bortezomib in the Treatment of Multiple Myeloma
Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promisin...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Basel :
Springer Basel : Imprint: Springer,
2011.
|
| Edición: | 1st ed. 2011. |
| Colección: | Milestones in Drug Therapy,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-7643-8948-2 | ||
| 003 | DE-He213 | ||
| 005 | 20220116005607.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 101029s2011 sz | s |||| 0|eng d | ||
| 020 | |a 9783764389482 |9 978-3-7643-8948-2 | ||
| 024 | 7 | |a 10.1007/978-3-7643-8948-2 |2 doi | |
| 050 | 4 | |a RC254-282 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Bortezomib in the Treatment of Multiple Myeloma |h [electronic resource] / |c edited by Irene M. Ghobrial, Paul G. Richardson, Kenneth C. Anderson. |
| 250 | |a 1st ed. 2011. | ||
| 264 | 1 | |a Basel : |b Springer Basel : |b Imprint: Springer, |c 2011. | |
| 300 | |a VIII, 180 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Milestones in Drug Therapy, |x 2296-6064 | |
| 520 | |a Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry. | ||
| 650 | 0 | |a Oncology. | |
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Cell death. | |
| 650 | 1 | 4 | |a Oncology. |
| 650 | 2 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Pharmacology. |
| 650 | 2 | 4 | |a Cell Death. |
| 700 | 1 | |a Ghobrial, Irene M. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Richardson, Paul G. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Anderson, Kenneth C. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783764389512 |
| 776 | 0 | 8 | |i Printed edition: |z 9783034800990 |
| 776 | 0 | 8 | |i Printed edition: |z 9783764389475 |
| 830 | 0 | |a Milestones in Drug Therapy, |x 2296-6064 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-3-7643-8948-2 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||